Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00190658
Status:
COMPLETED
Last Update Posted:
2010-12-20
First Post:
2005-09-12
Brief Title:
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Safety and Efficacy of Humatrope in Pediatric Patients With Genetic Short Stature SHOX Gene Defect
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency Both groups will be compared to a somatropin-treated group of girls with Turner syndrome After the second year patients in the control group have the option to receive treatment as well All patients will optionally be treated until they achieved adult height
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B9R-MC-GDFN | None | None | None |